secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001437749-24-032612
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Therapeutics prices $19.2M public stock offering at $16.25 per share
----------------------------------------------------------------------------

- Gross proceeds ~$19.2M from offering of up to 1,181,540 shares at $16.25/share.
- Participating investors include Janus Henderson, RA Capital Management, L.P.
- Net proceeds to be used for R&D, clinical trials, manufacture, and working capital.
- Offering closed October 30, 2024; Rodman & Renshaw acted as placement agent.
- Placement agent fee is 7.0% of gross proceeds plus expense reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924032612/0001437749-24-032612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924032612/mnpr20241029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-032612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer